EP Patent

EP0321613A1 — The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions

Assigned to Bristol Myers Co · Expires 1989-06-28 · 37y expired

What this patent protects

Pharmaceutical composition and process for administering NSAIDs with a combination of beta-adrenergic agonist and certain H₁-and H₂-receptor blockers which protect against injury to the gastrointestinal tract.

USPTO Abstract

Pharmaceutical composition and process for administering NSAIDs with a combination of beta-adrenergic agonist and certain H₁-and H₂-receptor blockers which protect against injury to the gastrointestinal tract.

Drugs covered by this patent

Pepcid (famotidine) · Generic (originally Yamanouchi/Merck)

Patent Metadata

Patent number: EP0321613A1
Jurisdiction: EP
Classification: —
Expires: 1989-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.